Introduction
Sepsis is defined as life-threatening organ dysfunction caused by an overwhelming immune response to infection and is the leading cause of death in intensive care units (ICU) worldwide [101] . The incidence of sepsis in high income countries is approximately 30 million/year and is associated with an annual mortality of 5.3 million/year [42] . Due to the aging population and the increasing number of drug-resistant infections the annual incidence of sepsis continues to rise.
Sepsis is a pathophysiological syndrome characterized by a continuum of severity culminating in septic shock [101] . Septic shock is characterized by refractory hypotension, hyperlactatemia and organ dysfunction that persists after aggressive fluid resuscitation [96] . The transition from sepsis to septic shock and organ failure can occur rapidly, but the mechanisms driving the dysfunction of interconnected organ systems remain unclear. The kidneys are frequently affected by sepsis leading to acute kidney injury (AKI). AKI develops in up to 50% of patients with sepsis, one-third of whom succumb to this condition [7] [8] [9] . The development of AKI in sepsis and septic shock significantly complicates its management and is associated with unfavorable health outcomes. Recent epidemiological studies have generated evidence that survivors of even mild or short episodes of AKI are predisposed to a greater risk of developing chronic and end-stage kidney disease in later life [24, 46, 86] . Thus, understanding the pathophysiology of septic AKI is important.
Septic AKI is diagnosed as an increase in serum creatinine and/or a decrease in urinary output in the presence of sepsis [11, 59] . From an epidemiologic point of view, it is defined by the simultaneous presence of the recent Sepsis-3 consensus criteria for sepsis [101] and the Kidney Disease Improving onset tissue ischemia and hypoxia selective to the renal medulla has been observed, despite increases in total RBF and whole kidney oxygen delivery [21, 71, 73] . Indeed, sepsis-induced renal hyperemia was accompanied by increased renal cortical tissue perfusion and oxygenation. These heterogenous changes in regional-kidney perfusion and oxygenation occurred several hours prior to the detection of AKI, as evaluated by the development of oliguria and increased plasma creatinine and urinary neutrophil gelatinase-associated lipocalin [21, 71, 73] . Mechanisms potentially responsible for the redistribution of intra-renal perfusion away from the medulla in sepsis include the excessive release of inflammatory cytokines [2] , regional deficits in nitric oxide-mediated vasodilation [54] , generation of reactive oxygen and nitrogen species [103] , damage to the glycocalyx [86] , and disruption to the endothelial barrier [14] , all possibly culminating in medullary hypoxia ( Figure 1 ). An early onset of renal medullary tissue hypoxia during sepsis can initiate a vicious cycle of oxidative stress and inflammation that can lead to mitochondrial dysfunction, tubular cell injury, and reduced kidney function ( Figure 1 ) [10, 17, 37, 41, 49, 61] .
Theoretical considerations:
Renal tissue oxygenation is determined by the balance between local oxygen delivery and consumption. In the kidney, oxygen delivery is determined not just by total RBF, but also by the distribution of such blood flow to the cortical and medullary circulations [39] . There is also evidence that diffusive shunting of oxygen, between arteries and veins in the cortex and descending and ascending vasa recta in the medulla, may further limit oxygen delivery to renal tissue [40] . Oxygen consumption in renal tissue is dominated
Accepted Article
This article is protected by copyright. All rights reserved.
by the energy requirements of the sodium-potassium ATPase needed to drive tubular sodium reabsorption. Consequently, renal oxygen consumption is directly linked to the filtered load of sodium, and thus glomerular filtration rate [40] . Thus, the effects of goal-directed therapies such as fluid resuscitation and vasopressor drugs on renal tissue oxygenation reflect a complex interaction between their effects on global and regional kidney tissue blood flow and tubular function. Importantly, any therapy that increases glomerular filtration rate would be expected to increase renal oxygen consumption and in turn, potentially promote renal tissue hypoxia. Thus, the implementation of current therapies for patients with septic AKI, and the development of new interventions, must begin with recognition of RBF-dependent oxygen demand on the renal microcirculation.
Hemodynamic management of septic shock and acute kidney injury
Fluids: Central hemodynamic support with aggressive fluid bolus therapy (20 mL/Kg) is the recommended first-line approach for patients with sepsis and septic AKI and is believed to improve renal perfusion and oxygenation by correcting hypovolemia [96] . Experimental studies in hemorrhagic and endotoxemic rats, however, have failed to demonstrate any improvement in renal cortical or medullary tissue oxygenation in response to fluid resuscitation [1, 56, 75] . However, such rodent models of sepsis were characterized by a hypodynamic circulation, thus confounding septic shock with simultaneous cardiogenic shock. Recent multicenter randomized trials using aggressive fluid-based resuscitation strategies have also failed to show any improvement in renal outcomes or mortality [83, 88, 109] . Moreover, evaluation of renal functional indices in patients with sepsis
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This article is protected by copyright. All rights reserved. revealed no beneficial effects of aggressive fluid bolus therapy on the incidence and progression of AKI [60] . Thus, the mechanisms by which fluid resuscitation might influence the renal macro-and microcirculation must be carefully evaluated in animal models of hyperdynamic sepsis and AKI that more closely mimic the human septic phenotype to develop effective evidence-based interventions. In septic shock, if fluid resuscitation fails to adequately correct the underlying hypotension, organ hypoperfusion, and hyperlactatemia, clinicians are then faced with the need to implement vasopressor therapy.
Vasopressor Therapy
Norepinephrine: In septic shock, norepinephrine is the first-choice vasopressor recommended to restore mean arterial blood pressure to ≥65 mmHg [96] , and potentially even to levels above 80 mmHg in patients with pre-existing hypertension [5] . Norepinephrine increases arterial pressure by α-adrenergic receptor-mediated vasoconstriction, with a small β-adrenergic receptor-mediated increase in stroke volume and thus CO [51, 91] . The renal benefits of using norepinephrine in septic AKI remain controversial due to the fear of it inducing further deterioration in renal function by causing localized renal vasoconstriction and ischemia [12, 51, 91] . However, norepinephrine therapy has been shown to consistently reverse hypotension and transiently improve renal function in septic shock, as evaluated by estimated glomerular filtration rate, with fewer adverse effects than dopamine, vasopressin, epinephrine, or phenylephrine [29, 81, 85, 98] . These findings, amongst others, have
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A major unresolved clinical problem encountered during the treatment of septic shock is that 15-20% of patients become unresponsive to norepinephrine [63, 66, 78] . In the setting of refractory septic shock, high doses of norepinephrine (0.5-1.0 µg/kg/min) [18] are required to attain target blood pressure, and this is associated with a substantially increased mortality rate, ranging from 60 to 100% [6, 18] . The high mortality rate associated with catecholamine-resistant septic shock can be attributed to refractory hypotension leading to reduced organ perfusion and organ failure and/or to direct adverse effects of the high levels of catecholamines and their metabolites on organ systems [58, 61, 72] . Several mechanisms are proposed to account for the pathogenesis of refractory hypotension in septic shock, including increased activity of vasodilators such as nitric oxide and prostanoids, an excessive opening of ATP-sensitive potassium channels, metabolic acidosis and increased levels of inflammatory cytokines [63, 66, 78] . Together, these mechanisms can lead to loss of vascular tone and hypo-responsiveness to vasopressors, causing severe hypotension, organ hypoperfusion, and potentially multiple-organ failure and death.
High doses of norepinephrine and the renal micro-circulation
Emerging experimental and clinical evidence demonstrate that there is "uncoupling" between the macro-and micro-circulation in response to vasoactive drugs in healthy and pathological states in non-renal and renal tissues. In a porcine model of septic shock, resuscitation with norepinephrine
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worsened microcirculatory flow abnormalities within the mesenteric circulation [65] . Similarly, there is clinical evidence that restoration of systemic hemodynamics with norepinephrine does not improve microcirculatory abnormalities in septic shock, as assessed by measurement of sublingual blood flow [30, 35, 55] . In the context of the renal microcirculation, it is becoming evident from experimental studies that alterations in regional-kidney perfusion and oxygenation cannot be reliably predicted from the assessment of global RBF and whole kidney oxygen delivery (RDO 2 ). In healthy sheep, intravenous infusion of norepinephrine dose-dependently reduced both renal cortical and medullary tissue oxygenation, despite preserved RBF and RDO 2 [20] . In septic sheep with established AKI, [24, 46, 86] . This provides the rationale for evaluating catecholamine-sparing strategies for septic shock that do not worsen the underlying pathological and reparative processes that occur during AKI.
Catecholamine-sparing strategies for septic shock and acute kidney injury
Vasopressin: Vasopressin is currently recommended as a rescue vasopressor for patients who are unresponsive to norepinephrine and/or for reducing the dose of norepinephrine required to attain target blood pressure [96] . Vasopressin increases arterial blood pressure chiefly by stimulating V 1 receptors located on vascular smooth muscle cells to induce vasoconstriction, and also by preventing the excessive opening of ATP-sensitive potassium channels in septic shock [97] . In the Vasopressin and Septic Shock Trial (VASST), mortality was not reduced by low-dose vasopressin (17-50 ng/min) therapy compared with high doses of norepinephrine (5-15 µg/min) [98] . However, a subgroup analysis of the VASST trial showed lower incidences of progression of septic AKI and mortality within the vasopressin treatment group [45] . Moreover, patients treated with vasopressin had greater improvements in urinary output and glomerular filtration rate than those treated with norepinephrine alone [45] . Similarly, in ovine septic AKI, low dose vasopressin (33 ng/min) has been reported to restore blood pressure and significantly improve renal function [34] . In healthy conscious sheep, infusion of vasopressin preserved renal cortical and medullary tissue perfusion and oxygenation [20] .
Within the renal vasculature, the magnitute of the V 1 receptor-mediated vasoconstriction by vasopressin has been demonstrated to be effectively modulated by vasodilator systems, such as nitric oxide and eicosanoids, specially in the renal cortex [27, 93] . This may explain the better maintenance of intra-renal perfusion and oxygenation in response to treatment with vasopressin when compared with norepinephrine in healthy sheep [20] . Together, these findings suggest that vasopressin at lower doses may offer a degree of renoprotection in the setting of septic AKI compared with high doses of
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Angiotensin II: Angiotensin II is potent vasoconstrictor acting via angiotensin type 1 receptors to increase arterial pressure [47] . In early ovine hyperdynamic sepsis, angiotensin II effectively restored arterial pressure and caused greater improvements in renal function than norepinephrine alone [33, 108] . In septic sheep and pigs, angiotensin II restored systemic hemodynamics without deleterious effects on other vital organs, biochemical variables or renal bioenergetics and also no further increases in arterial blood lactate or inflammatory cytokines [25, 80, 108] . In a pilot study in patients with catecholamine-resistant septic shock, angiotensin II effectively restored blood pressure and doubled renal function [22] .
The beneficial renal functional effects of angiotensin II in septic AKI may be due to its ability to induce a more profound increase in post-glomerular resistance compared with the pre-glomerular resistance, thus increasing glomerular perfusion pressure and filtration rate [32] . Importantly, angiotensin II has also been demonstrated to play an important role in resetting the lower limit of renal autoregulation, especially at lower renal perfusion pressures [28, 52, 102] . Together, these features of Ang II may account for its ability to maintain autoregulation of GFR, relative to RBF, at a reduced renal perfusion pressure in settings of systemic hypotension such as septic shock. In septic pigs, intravenous infusion of angiotensin II for 48-hours did not have any adverse effects on mitochondrial respiration in the kidney, heart or liver when compared with norepinephrine treatment
This article is protected by copyright. All rights reserved. [25] . After these initial safety and feasibility studies, a randomized, double-blinded, multicenter clinical trial in more than 300 patients with catecholamine-refractory vasodilatory shock validated angiotensin II as an effective rescue vasopressor to restore blood pressure (Angiotensin II for Treatment of High Output Shock (ATHOS)) [62] . Following the ATHOS trial, angiotensin II was approved for treatment of high output vasodilatory shock for humans by the U.S. Food and Drug Administration in December 2017. However, angiotensin II is currently not recommended as a primary vasopressor in septic shock due to its potential inflammatory and thrombotic actions, which may aggravate microcirculatory dysfunction [4, 26] . Further clinical investigations are required to determine the role of angiotensin II as a first-choice vasopressor therapy for vasodilatory shock, to identify the patients that are most likely to benefit and to further establish its safety.
In healthy conscious sheep, infusion of angiotensin II did not reduce renal cortical or medullary perfusion, which was in contrast to the intra-renal vasoconstrictor effects seen with norepinephrine [20] . In a recent study of established ovine septic AKI, angiotensin II used as a primary vasopressor was shown to effectively restore blood pressure and transiently increase renal function, in a manner similar to that seen during infusion of norepinephrine ( Figure 2) [71, 73] . Importantly, angiotensin II restored systemic hemodynamics and renal function without further compromising renal medullary perfusion and oxygenation, which occurred with norepinephrine (Figure 2 & 3) [71, 73] . Indeed, a subgroup analysis of the ATHOS trial involving 105 patients with septic AKI on renal replacement therapy at randomization showed a 23% relative reduction in risk of mortality and a more rapid recovery of renal function when angiotensin II (compared to placebo) was used as an adjunct therapy
This article is protected by copyright. All rights reserved. [107] . Together, these experimental and clinical findings suggest that angiotensin II may be a safer alternative primary vasopressor agent in the setting of septic AKI. α 2 -adrenergic receptor agonists: Dexmedetomidine and clonidine are routinely used as sedatives to reduce agitation and delirium in critically ill patients in ICUs [89, 94] . Such so-called 'centrally-acting α 2 -agonists' mainly act on the pre-synaptic α 2 -adrenergic receptors to inhibit norepinephrine release from both central and peripheral nerve terminals, thereby reducing overall sympathetic nerve activity [83] . Of relevance, administration of high doses of vasopressin (100 ng) directly into the area postrema has also been demonstrated to augment baroreflex-mediated inhibition of renal and lumbar sympathetic nerve activity in rodents [48] .
High plasma norepinephrine levels have been reported in non-survivors compared with survivors in a population of critically ill patients [15] . High levels of endogenous norepinephrine were also significantly associated with mortality in patients with septic shock [13] . Thus, the centrally acting sympatholytic actions of α 2 -adrenergic receptor agonists may improve prognosis by reducing the adverse effects of sympathetic overstimulation in septic shock. However, the use of centrally acting sympatholytics in the treatment of a hypotensive condition such as septic shock raises concerns because of their actions to reduce sympathetic nerve activity, which would be expected to enhance the degree of hypotension in septic shock and promote multi-organ failure. However, authors of studies in rodent models of sepsis have reported improved survival rates with dexmedetomidine and clonidine treatment [50, 105, 106] . In agreement, authors of clinical studies have also reported 8% and 20%
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A possible mechanism underlying the beneficial effects of α 2 -adrenergic receptor agonists was revealed by the recent finding that these drugs reverse vascular hypo-responsiveness in septic shock [43, 72] . Indeed, experimental studies using supra-therapeutic doses of clonidine (200 μg/kg) or dexmedetomidine (100 μg/kg) showed restoration of pressor responsiveness to norepinephrine in endotoxemic rats [43] . It has been proposed that this beneficial effect of α 2 -adrenergic receptor agonists is due to a reduction in sympathetic outflow leading to up-regulation of vascular smooth muscle α 1 -adrenergic receptors that were otherwise down-regulated in sepsis. More recently, these findings in rodents were validated in an ovine model of hyperdynamic sepsis, in which infusion of a clinically-relevant dose of clonidine (1 µg/kg/h) reduced the high levels of renal sympathetic nerve activity and restored pressor responsiveness to phenylephrine (Figure 4) [72] . In accord with these findings, two recent case reports showed that infusion of the same dose of clonidine (1 µg/kg/h) reduced the dose of norepinephrine required to maintain blood pressure by 45% in a patient with terminal pulmonary septic shock [90] and by 90% in a neonate with necrotizing enterocolitis [77] .
Interestingly, in ovine hyperdynamic sepsis, clonidine also restored sensitivity to a non-adrenergic receptor vasoconstrictor (angiotensin II) [72] . These findings suggest that the actions of α 2 -adrenergic receptor agonists to improve pressor responsiveness in septic shock may result from mechanisms that are either downstream or independent of α 1 -adrenergic receptors. Previously, in vitro functional studies in healthy rodents have demonstrated a potential synergism between the post-junctional angiotensin type 1 receptors and α 2 -adrenergic receptor agonists to potentiate vascular resistance
This article is protected by copyright. All rights reserved. [53, 74] . This interaction may be of relevance to the studies in ovine hyperdynamic sepsis that demonstrate a complete restoration in pressor responsiveness to angiotensin II following treatment with the α 2 -agonist, clonidine. However, further studies in clinically relevant models of sepsis are required to define the precise intra-cellular mechanisms involved.
There is a paucity of experimental and clinical data regarding the effects of α 2 -adrenergic receptor agonists on the renal microcirculation in the setting of septic AKI. In rodent models of sepsis, clonidine, and dexmedetomidine appear to improve renal function and outcomes [50, 105, 106] . In an ovine model of hyperdynamic sepsis and AKI, infusion of clonidine (1 µg/kg/h) reduced the degree of global renal hyperemia and doubled urinary output [19] . However, this diuretic response was dissociated from any changes in creatinine clearance or fractional excretion of sodium [19] . Similarly, a clinical study showed that renal function as indirectly estimated by serum creatinine, was neither superior nor inferior as a consequence of dexmedetomidine treatment in patients with septic shock [58] . Considering the experimental evidence that restoration of blood pressure with high doses of norepinephrine has unfavorable effects on renal medullary perfusion and oxygenation in septic AKI (Figures 2 & 3 ) [73] , reducing vasopressor requirements with α 2 -adrenergic receptor agonists may be a feasible strategy for minimizing the harmful effects of high levels of catecholamines on the renal microcirculation. Indeed, reducing doses of norepinephrine in septic shock is likely to have multiple other benefits considering the evidence that high doses of catecholamines and their metabolites lead to many adverse events. These deleterious effects include reductions in immune function and metabolic efficiency, stimulation of bacterial growth, increases in pulmonary artery pressure and increased mortality [3, 36, 82] .
Perspectives
The renal medulla appears to be particularly susceptible to ischemia and hypoxia in multiple forms of AKI, including septic shock. Indeed, renal tissue hypoxia due to redistribution of intra-renal perfusion is emerging as a critical pathophysiological aspect of septic AKI. High doses of norepinephrine appear to have deleterious effects on the renal microcirculation in healthy and pathophysiological states. Thus, vasopressor therapies aimed at restoring arterial pressure and renal function in septic AKI should be administered with caution, and with consideration of their effects on intrarenal tissue perfusion and oxygenation. Global kidney blood flow and whole kidney oxygen delivery appear to be poor predictors of regional-kidney perfusion and oxygenation. Thus, it is important that future experimental studies directly monitor the effects of new therapies on the renal microcirculation.
Recent experimental studies demonstrating adverse effects of high-doses of catecholamines on the renal microcirculation in septic AKI provides the impetus to explore the benefit of non-catecholamine vasopressor drugs, such as vasopressin and angiotensin II, and catecholamine-sparing interventional strategies, such as α 2 -adrenergic receptor agonists. However, it is important to be certain that new treatments do not worsen the underlying pathological processors that occur in septic AKI. Therapies that preserve renal medullary tissue perfusion and oxygenation in the early stages of sepsis may bring new hope towards reducing the development and/or progression of AKI and improving the health outcomes of these critically ill patients.
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